GlassScriptPhysician profile
Amanda Hooper
NPI 1215232731
$2,485.13
in general payments reported to CMS, 2019-2025
8 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $497 · 2022: $659 · 2023: $294 · 2024: $608 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,329.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $615.71 | 2022-2025 | Kimyrsa |
| Abbvie INC. | $514.97 | 2021-2025 | |
| Kci USA, INC. | $458.48 | 2021-2023 | V.A.C. Veraflo, V.A.C. Dermatac, Activ.A.C. |
| Paratek Pharmaceuticals, INC. | $395.72 | 2021-2024 | Nuzyra |
| Penumbra, INC. | $240.32 | 2021-2023 | Indigo System |
| Becton, Dickinson and Company | $123.96 | 2024 | Crosser Iq |
| E.R. Squibb & Sons, L.L.C. | $101.67 | 2025 | Sotyktu |
| Solventum Corporation | $34.30 | 2024 | Activ.A.C., Promogran Prisma, V.A.C. Dermatac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Hooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.